Secretory phospholipase A2 in patients with coronary artery disease.
This study investigated the correlation of sPLA2 (secretory phospholipase A2) activity with the atheromatosis extent in subjects with coronary artery disease (CAD) undergoing coronary angiography. We analyzed 123 patients, including 35 subjects with angiographically normal coronary arteries (controls), 31 with mild/moderate atheromatosis (stenosis of 30-70% of the luminal diameter in one or more coronary arteries) and 57 with severe atheromatosis (>70% stenosis). Plasma sPLA2 activity was significantly higher in subjects with severe [127.7 U/ml (102.3-162.7); p < 0.0001] and mild/moderate [112.0 U/ml (100.6-146.9); p < 0.0001] atheromatosis than in controls [19.8 U/ml (15.1-32.1)]. In a multiple logistic regression model, adjusted for age, gender, body mass index, tabagism, hypertension, sedentarism, family history for coronary artery disease, diabetes mellitus, total cholesterol, HDLc, LDLc, triglycerides, high sensitivity C-reactive protein and phospholipase A2, only sPLA2 was observed to be independently associated with severe CAD (>70% of stenosis) (p < 0.0001).
Lima
Luciana Moreira
LM
Faculdade de Farmácia, Universidade Federal de Minas Gerais, Av. Antônio Carlos. 6627, Belo Horizonte, Minas Gerais, CEP 31270-901, Brazil.
Carvalho
Maria das Graças
Md
da Fonseca Neto
Cirilo Pereira
CP
Garcia
José Carlos Faria
JC
Sousa
Marinez Oliveira
MO
D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000097:blood / Q000000981:diagnostic imaging* / Q000201:enzymology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D054497:Phospholipases A2, Secretory / Q000097:blood*; D011446:Prospective Studies; D012307:Risk Factors
D015415:Biomarkers; D054497:Phospholipases A2, Secretory